XRPMSNCT04876781
Korean Post-marketing Surveillance for Xeljanz XR
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 26 versions: 10 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 15 words Show 4 more changesShow less
- Trial completed
- Primary and study completion dates changed from estimate of Sep 22, 2026 to Oct 20, 2026
- Secondary endpoints: details revised at 2 of 5 entries
- Site details revised
- Minor Primary and study completion pushed from Jun 30, 2026 to Sep 22, 2026v24
- Minor Primary and study completion dates: Dec 6, 2026 to Jun 30, 2026v20
- Notable Primary and study completion dates: Jun 30, 2024 to Dec 6, 2026v13
- Minor Primary and study completion dates: May 31, 2025 to Jun 30, 2024
- Study description expanded, about 92 words
Show 4 earlier versionsHide 4 earlier versions
- Notable Eligibility criteria expanded, about 131 words
- Primary endpoint revised
- Secondary endpoints: 4 to 5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Nov 1, 2021 to Jan 12, 2022
- Notable Eligibility criteria expanded, about 4 words
- Secondary endpoints: 3 to 4
- Notable Start date: Jul 1, 2021 to Nov 1, 2021v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants With Treatment Emergent Adverse Events (AEs)
Timeframe: Maximum of 52 weeks from the time of initial administration of Xeljanz XR
Secondary (5)
Change from baseline in Disease Activity Score based on 28-joints Count (DAS28)
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
Number of Participants With an American College of Rheumatology 20% (ACR20) Response
Assessment of Ankylosing Spondylitis response (ASAS20)
Changes from baseline in the number of tender joints and swollen joints
Arms and interventions
Drugs: Tofacitinib XR
Sites
1 site in 1 country
- PfizerSeoul, South Korea